Reviva’s Brilaroxazine Demonstrates Efficacy and Safety in Long-Term Schizophrenia Treatment

Efficacy in Phase 2 Trial:

Brilaroxazine, developed by Reviva Pharmaceuticals, showed significant efficacy in reducing symptoms of schizophrenia in a Phase 2 clinical trial. The drug reduced the Positive and Negative Syndrome Scale (PANSS) total score by 20 points, a statistically significant difference from the placebo1.

Safety Profile:

The drug demonstrated a safety profile comparable to placebo, with no significant metabolic, endocrine, or suicidal ideation side effects compared to placebo14.

Phase 3 RECOVER Trial:

The Phase 3 RECOVER trial further supported the efficacy of brilaroxazine across multiple symptom domains of schizophrenia, including negative symptoms and cognitive functioning, with a generally well-tolerated side effect profile4.

Vocal Biomarker Data:

New vocal biomarker data from the RECOVER trial provided objective evidence of brilaroxazine's efficacy in reducing negative symptoms and other key symptoms of schizophrenia4.

Potential Impact:

Brilaroxazine addresses unmet needs in schizophrenia treatment by offering a broad spectrum of efficacy with a favorable safety profile, potentially improving treatment adherence and outcomes for patients with schizophrenia14.

Sources:

1. https://revivapharma.com/reviva-announces-full-details-of-positive-phase-2-clinical-trial-results-for-acute-schizophrenia/

4. https://revivapharma.com/reviva-announces-new-vocal-biomarker-data-from-phase-3-recover-trial-of-brilaroxazine-in-schizophrenia/